Abstract
A novel approach to current radiopharmaceutical study design to document the efficiency of 177Lu- PSMA-radioligand therapy of metastatic prostate cancer is described in a proposed prospective, real-time, realworld audit of a large patient population worldwide. The NIGHTCAP (National Investigators Global Harmonisation Theragnostics of Cancer of Prostate) Study will establish real-world evidence (RWE) of overall survival (OS) and quality of life (QoL) in patients undergoing routine 177Lu-PSMA-radioligand therapy on harmonised compassionate patient-usage protocols throughout the world. Such long-term efficiency data will be contrasted with the short-term randomised controlled trial (RCT) assessments of efficacy predicated upon surrogate markers of survival outcomes, such as progression-free survival (PFS). The shortcomings of RCT evaluation of the clinical benefit of new anticancer agents are detailed in this review, which advocates RWE to determine efficiency.
The real-time monitoring of QoL in the NIGHTCAP Study is independent of questionnaires, language differences, or oncologist bias, and relies upon individual patient self-assessment by choice of one of five emoji which best reflects their mood each day.
Keywords: Theragnostics, Real-world Data, efficiency, Lutetium-177-PSMA Radio-ligand Therapy, prostate cancer, NIGHTCAP Study.
[http://dx.doi.org/10.1016/j.ctrv.2018.12.003] [PMID: 30572165]
[http://dx.doi.org/10.1038/s41571-019-0169-5] [PMID: 30718844]
[http://dx.doi.org/10.1089/cbr.2019.29006.jht] [PMID: 30973278]
[http://dx.doi.org/10.1038/s41571-019-0230-4] [PMID: 31110270]
[http://dx.doi.org/10.1016/j.cct.2018.01.003] [PMID: 29330082]
[http://dx.doi.org/10.1200/JCO.19.00382] [PMID: 30995173]
[http://dx.doi.org/10.1038/s41591-018-0314-1] [PMID: 30617334]
[http://dx.doi.org/10.1056/NEJMra1701695] [PMID: 29412780]
[http://dx.doi.org/10.1200/JCO.18.00729] [PMID: 30707056]
[http://dx.doi.org/10.1200/JCO.19.01073] [PMID: 31339826]
[http://dx.doi.org/10.1016/j.ejca.2017.04.003] [PMID: 28522211]
[http://dx.doi.org/10.1056/NEJMoa1805104] [PMID: 30184451]
[http://dx.doi.org/10.1038/nrclinonc.2017.153] [PMID: 28975931]
[http://dx.doi.org/10.1200/JCO.2017.76.0488] [PMID: 29236571]
[http://dx.doi.org/10.1038/s41571-018-0030-2] [PMID: 29760505]
[http://dx.doi.org/10.1111/imj.13652] [PMID: 29068529]
[http://dx.doi.org/10.1200/JCO.18.02320] [PMID: 31233352]
[http://dx.doi.org/10.1016/S1470-2045(17)30954-3] [PMID: 29276024]
[http://dx.doi.org/10.1038/d41591-019-00010-z]
[http://dx.doi.org/10.1038/s41571-019-0167-7] [PMID: 30700859]
[http://dx.doi.org/10.1200/JCO.18.01074] [PMID: 30897037]
[http://dx.doi.org/10.1259/bjr.20180308] [PMID: 29762048]
[http://dx.doi.org/10.1007/s00259-017-3895-x] [PMID: 29247284]
[http://dx.doi.org/10.1016/j.euf.2016.09.008] [PMID: 28753794]
[http://dx.doi.org/10.1016/S1470-2045(18)30198-0]
[http://dx.doi.org/10.1007/s00259-019-04485-3] [PMID: 31440799]
[http://dx.doi.org/10.1007/s00259-018-4222-x] [PMID: 30474706]
[http://dx.doi.org/10.2967/jnumed.117.203539] [PMID: 29326358]
[http://dx.doi.org/10.1200/JCO.2015.63.0830] [PMID: 26644527]
[http://dx.doi.org/10.1186/1477-7525-4-79] [PMID: 17034633]
[http://dx.doi.org/10.1056/NEJMp1611252] [PMID: 28076708]
[http://dx.doi.org/10.1200/JCO.19.01584] [PMID: 31343906]